Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Image of Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

THERAPEUTIC CLASS

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhang Y - Personal Name;

With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19, containing inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for its safety, tolerability and immunogenicity

Availability

Location name is not set Location name is not set

REQJ4250-1

Available

Detail Information

Series Title: -
Call Number: -
Publisher: : .,
Collation: -
Language: English
ISBN/ISSN: -
Classification: NONE
Content Type: LITERATURE
Media Type: -
Carrier Type: -
Edition: -
Subject(s): Allergy & Immune System
Specific Detail Info: https://doi.org/10.1016/S1473-3099(20)30843-4
Statement of Responsibility: -

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Availability

Detail Information

Other version/related

File Attachment

Comments